Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.


BACKGROUND Behçet's disease is a multisystem vasculitis of unknown origin. Standard treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly posterior uveitis with retinal vasculitis, leads to blindness in 20-50% of the involved eyes within 5 years. The efficacy of interferon alfa-2a was studied in patients with sight… (More)


9 Figures and Tables